Richard C. Pasternak , MD, Chairman of the Scientific Advisory Board
Dr. Pasternak retired from Merck in 2011. During his tenure at Merck, Dr. Pasternak was the Vice President, Clinical Research, leading the Cardiovascular/Atherosclerosis Clinical Research Department, and later was the Vice President, Head of Global Scientific Affairs and Scientific Leadership. He also chaired the R & D oversight committee for the Merck-Schering Plough Joint Venture on drug development for hypercholesterolemia. Prior to joining Merck, Dr. Pasternak was the Director of Preventive Cardiology and Cardiac Rehabilitation at the Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. As a faculty member of the Harvard Medical School, he was the Director of Coronary Care Unit at Beth Israel Hospital, and later established a new Section of Preventive Cardiology at Massachusetts General Hospital. Dr. Pasternak earned his BA and MD degrees from Yale University.
Steven B. Heymsfield, MD
Dr. Heymsfield, is the George A. Bray, Jr. Endowed Super Chair in Nutrition and Professor at the Pennington Biomedical Research Institute. He previously served as Executive Director of the Institute. Prior to joining the Pennington, Dr. Heymsfield served as Global Director for scientific affairs and obesity at Merck & Co. Prior to Merck, he was the Director of the Human Body Composition Laboratory and Weight Control Unit as well as Deputy Director of the New York Obesity Research Center at St. Luke’s-Roosevelt Hospital in Manhattan. In addition, he was a Professor of Medicine at Columbia University College of Physicians and Surgeons and a Visiting Scientist at Rockefeller University and the Brookhaven National Laboratory at Long Island, New York. Dr. Heymsfield, is a past president of both the American Society of Clinical Nutrition and the American Society of Parenteral and Enteral Nutrition
Peter H. Jones, MD
Dr. Jones is Co-Director of the Lipid Metabolism and Atherosclerosis Clinic and Medical Director of the Weight Management Center at The Methodist Hospital. He is Associate Professor in the Department of Medicine, Section of Atherosclerosis and Lipid Research at the Baylor College of Medicine. Dr. Jones is a Fellow of the American College of Physicians and Fellow of the Council on Arteriosclerosis and Thromobosis of the American Heart Association. Dr. Jones’ research has focused on clinical evaluation of new lipid-modifying drugs and fixed-dose lipid drug combinations. His research has also focused on the effects of weight reduction with very-low-calorie diets on plasma markers of inflammation and insulin sensitivity.
Virginia E. Kimonis, MD, MCRP
Dr. Kimonis is the principal investigator for Essentialis’ PC025 clinical study. She is Professor of Pediatrics in the Division of Genetics and Metabolism at the University of California, Irvine School of Medicine. Previously, Dr. Kimonis was a Professor of Pediatrics at Harvard Medical School. Dr. Kimonis is a Clinical Geneticist-Scientist with a strong interest in the genetics of neuromuscular diseases. She also holds appointments with Long Beach Memorial/Miller Children’s Hospital, Long beach, CA and Childrens Hospital of Orange County (CHOC) Dr. Kimonis has established UC Irvine as a RDRCN (Rare Diseases Clinical Research Network) site for the Natural History study of Prader Willi and Morbid Obesity syndrome.